Overall survival (non‐taxane monotherapy vs taxane monotherapy) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in overall survival (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (non‐taxane containing therapy vs another non‐taxane containing therapy) · advanced gastric adenocarcinoma
1 finding from 1 review
Progression‐free survival (PSF) · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).
3 findings from 1 review
HR 1.14 [0.88, 1.48]
1 study · 219 participants
Low
HR 0.75 [0.52, 1.09]
2 studies · 121 participants
Low
no estimate extracted
1 study · 107 participants
High
Tumour response · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
2 findings from 1 review
Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).
1 finding from 1 review
Chemotherapy compliance · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Radiotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to lower radiotherapy compliance compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Chemotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to lower chemotherapy compliance compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Participants requiring chemotherapy delays · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in overall survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher progression‐free survival compared with biological therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy may leads to lower serious adverse events compared with biological therapy (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower any adverse events compared with biological therapy (moderate certainty).
1 finding from 1 review
Serious adverse effects · advanced gastric adenocarcinoma
1 finding from 1 review
Adverse events · advanced gastric adenocarcinoma
1 finding from 1 review
Quality of life · advanced gastric adenocarcinoma
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy compared with primary surgery (moderate certainty).
1 finding from 1 review